Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Clearside Biomedi (CLSD)

Clearside Biomedi (CLSD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 123,024
  • Shares Outstanding, K 44,413
  • Annual Sales, $ 30 K
  • Annual Income, $ -82,820 K
  • 60-Month Beta 0.05
  • Price/Sales 377.55
  • Price/Cash Flow N/A
  • Price/Book 10.22

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.06
  • Number of Estimates 3
  • High Estimate 0.00
  • Low Estimate -0.16
  • Prior Year -0.68
  • Growth Rate Est. (year over year) +91.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.35 +17.87%
on 02/18/20
4.13 -32.93%
on 02/03/20
-0.07 (-2.46%)
since 01/17/20
3-Month
0.97 +185.57%
on 11/20/19
4.13 -32.93%
on 02/03/20
+1.73 (+166.35%)
since 11/19/19
52-Week
0.56 +394.64%
on 08/28/19
4.13 -32.93%
on 02/03/20
+1.32 (+91.03%)
since 02/19/19

Most Recent Stories

More News
Clearside Biomedical Announces Presentations to be Given at Angiogenesis and Macula Society Conferences

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases,...

CLSD : 2.77 (+4.92%)
Bausch Health and Clearside Biomedical Announce Publication of PIVOTAL Phase 3 Data ON XIPERETM (triamcinolone acetonide suprachoroidal injectable suspension) in Ophthalmology

Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and Bausch + Lomb, its leading global eye health business, and Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated...

CLSD : 2.77 (+4.92%)
Ocular Drug Delivery Market 2019 Global Leading Players, Industry Updates, Future Growth, Business Prospects, Forthcoming Developments and Future Investments by Forecast to 2025

Ocular Drug Delivery Market 2019 Report offers a professional and in-depth study on the current state of the Global Ocular Drug Delivery Market along with competitive landscape, Ocular Drug Delivery Market...

ALIM : 6.15 (-1.76%)
AGN : 198.81 (+0.41%)
CLSD : 2.77 (+4.92%)
OCUL : 5.29 (+0.76%)
SNPHF : 19.3000 (-0.26%)
VRX.TO : 30.80 (-3.33%)
Will Clearside Biomedical Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in Clearside Biomedical.

CLSD : 2.77 (+4.92%)
Clearside Biomedical to Present at the 38th Annual J.P. Morgan Healthcare Conference

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases,...

JPM : 137.49 (+1.36%)
CLSD : 2.77 (+4.92%)
Ocular Drug Delivery Technology Market Research Report 2020 - Industry Statistical Study Of The Forecast Years 2020-2029

An extensive and elaborate primary research on Global Ocular Drug Delivery Technology Market report sheds light on numerous facets such as growth factors, statistical growth, business enhancement strategies,...

ALIM : 6.15 (-1.76%)
AGN : 198.81 (+0.41%)
CLSD : 2.77 (+4.92%)
NVS : 97.22 (+0.02%)
OCUL : 5.29 (+0.76%)
PFE : 36.23 (-0.25%)
VRX.TO : 30.80 (-3.33%)
Biotech Leading in Q4: Best ETFs & Stocks

We highlight five biotech ETFs and stocks that are leading the market in Q4.

SNY : 50.71 (-0.84%)
MRK : 82.00 (-0.56%)
RHHBY : 44.7300 (+1.44%)
NVS : 97.22 (+0.02%)
CNCR : 22.60 (+1.16%)
SBIO : 42.55 (-0.15%)
XBI : 98.35 (+0.76%)
BBC : 38.41 (+0.48%)
THOR : 67.99 (unch)
SRPT : 121.90 (-0.72%)
GBT : 71.35 (+0.27%)
VRTX : 247.78 (+0.75%)
AXSM : 92.15 (+0.08%)
CLSD : 2.77 (+4.92%)
Is the Options Market Predicting a Spike in Clearside Biomedical (CLSD) Stock?

Investors need to pay close attention to Clearside Biomedical (CLSD) stock based on the movements in the options market lately.

CLSD : 2.77 (+4.92%)
Ocular Drug Delivery Technology Market : Discussion Of Market Drivers, Key Vendors And Challenges With Forecast To 2024

Ocular drug delivery refers to the treatment of ophthalmic diseases. Ophthalmic diseases affect various parts of the eye anatomy, are specified on the basis of their position namely, anterior segment and...

CLSD : 2.77 (+4.92%)
NVS : 97.22 (+0.02%)
PFE : 36.23 (-0.25%)
VRX.TO : 30.80 (-3.33%)
Clearside Biomedical to Present at the Stifel 2019 Healthcare Conference

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases,...

CLSD : 2.77 (+4.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade CLSD with:

Business Summary

Clearside Biomedical, Inc. is a biopharmaceutical company is engaged in developing first-in-class drug therapies to treat blinding diseases of the eye using Clearside proprietary suprachoroidal space(TM) microinjector. Its products include CLS-1001 for the treatment of macular edema associated with non-infectious...

See More

Key Turning Points

2nd Resistance Point 2.98
1st Resistance Point 2.87
Last Price 2.77
1st Support Level 2.63
2nd Support Level 2.50

See More

52-Week High 4.13
Fibonacci 61.8% 2.77
Last Price 2.77
Fibonacci 50% 2.35
Fibonacci 38.2% 1.92
52-Week Low 0.56

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar